Gaudium IVF and Women Health Ltd

After a sustained four-day rally delivering nearly 20% returns, Gaudium IVF and Women Health Ltd surged to a fresh 52-week and all-time high of Rs 135.5 on 14 Jul 2026, outperforming its healthcare services sector by 4.63% on the day despite a broadly weaker market backdrop.

After a steady climb over recent weeks, Gaudium IVF and Women Health Ltd touched a fresh all-time high of Rs 135.50 on 14 Jul 2026, marking a significant milestone for the healthcare services micro-cap. This surge comes amid a broader sideways technical trend and stretched valuation multiples, raising questions about the sustainability of the current momentum.

Gaudium IVF and Women Health Ltd, a micro-cap player in the Healthcare Services sector, has experienced a notable shift in price momentum and technical indicators, prompting a downgrade in its Mojo Grade from Hold to Sell as of 6 July 2026. The stock’s recent price action and technical signals suggest a transition from a mildly bullish trend to a sideways consolidation phase, raising questions about its near-term trajectory amid broader market dynamics.

At Rs 125.13, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Gaudium IVF and Women Health Ltd locked at its upper circuit of 4.99% on 10 Jul 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 107.84, sellers were still queuing — but there were no buyers willing to take the other side. Gaudium IVF and Women Health Ltd locked at its lower circuit of 5% on 9 Jul 2026, with unfilled sell orders and a frozen price.

Gaudium IVF and Women Health Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the healthcare services sector.

At Rs 113.51, sellers were still queuing — but there were no buyers willing to take the other side. Gaudium IVF and Women Health Ltd locked at its lower circuit of 5.0% on 07 Jul 2026, with unfilled sell orders and a frozen price, reflecting a day where supply overwhelmed demand to the point the exchange intervened.

Gaudium IVF and Women Health Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent day decline of 3.17%, the stock’s technical indicators suggest a cautiously optimistic outlook, supported by evolving MACD, RSI, and moving average signals.

Gaudium IVF and Women Health Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 July 2026, providing investors with the latest insights into its performance and outlook.

Gaudium IVF and Women Health Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a robust short-term price rally, key technical indicators present a nuanced picture, prompting a downgrade in its Mojo Grade from Hold to Sell as of 6 July 2026.

At Rs 122.74, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Gaudium IVF and Women Health Ltd locked at its upper circuit of 5.0% on 6 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Gaudium IVF and Women Health Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. Despite this, the micro-cap healthcare services company has demonstrated positive price momentum, outperforming the Sensex over the past week. This article analyses the recent valuation changes, compares key financial metrics with peers, and assesses the implications for investors.

Gaudium IVF and Women Health Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 26 June 2026, providing investors with an up-to-date analysis of the company’s standing.

Gaudium IVF and Women Health Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. This change is underscored by recent price action, technical indicator signals, and a revised Mojo Grade, reflecting evolving investor sentiment in the healthcare services sector.

Gaudium IVF and Women Health Ltd, a micro-cap player in the healthcare services sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.96%, recent technical indicators suggest caution for investors as momentum oscillators and moving averages signal a potential deceleration in price strength.

Gaudium IVF and Women Health Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 1.97% to close at ₹101.10, the stock’s broader performance and technical indicators suggest a complex outlook amid subdued returns compared to the Sensex benchmark.

Gaudium IVF and Women Health Ltd is rated Sell by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Gaudium IVF and Women Health Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish trend. This change is underscored by a series of technical indicator signals, including the MACD, RSI, and moving averages, which collectively suggest increasing downside pressure on the stock amid broader market challenges.